Anti-Mouse/Human IL-5 - Purified
| Code | Size | Price |
|---|
| LEI-I-1038-50ug | 50 ug | £199.00 |
Quantity:
| LEI-I-1038-500ug | 500 ug | £290.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rat
Antibody Isotype: IgG1
Antibody Clonality: Monoclonal
Antibody Clone: TRFK5
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Shipping:
2-8°C
Storage:
This Purified conjugate is stable when stored at 2-8°C. Do not freeze.
Further Information
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified
Format:
This Purified conjugate is formulated in 0.01 M phosphate buffered saline (PBS) pH 7.4, 150 mM NaCl, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This Purified conjugate is formulated in 0.01 M phosphate buffered saline (PBS) pH 7.4, 150 mM NaCl, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Partially-purified T cell clone supernatant
Long Description:
IL-5 is a 26 kD TH2 cytokine and a homodimeric glycoprotein that is part of the hematopoietic family. IL-5 stimulates B cell growth as well as increases Ig secretion. It is the main factor that promotes the terminal differentiation of eosinophil progenitors and enhances the effector capacity of mature eosinophils. IL-5 is a major regulator of eosinophil accumulation in tissues. In fact, in Hodgkin lymphoma, the characteristically observed eosinophilia is suspected to result from an increased production of IL-5. IL-5 may also be the cause of several allergic diseases including asthma, where it is thought that eosinophils have a significant role in the disease pathology. There are several mAbs currently in use that target IL-5 for the treatment of severe eosinophilic asthma.
NCBI Gene:
161913567
Target:
IL-5
Related Products
| Product Name | Product Code | Supplier | Anti-Mouse/Human IL-5 - Purified in vivo PLATINUM™ Functional Grade (DISCONTINUED) | LEI-I-1192 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|